Ankylosing spondylitis
New approaches to treating ankylosing spondylitis are needed experts warn
Common and modifiable factors that predict poor quality of life in people with ankylosing spondylitis have been highlighted in research from the University of Aberdeen. Continue reading
UK’s largest arthritis charities merge
Arthritis Care will merge into Arthritis Research UK and work as one charity from October 2017. Continue reading
Genetic variants associated with ankylosing spondylitis are more common than previously thought
A new insight into the genetics of ankylosing spondylitis could aid future treatment of the disease, says research in the Proceedings of the National Academy of Sciences.
Continue reading
Longer-lasting pain relief thanks to compound – new developments
Experts are developing compounds that could allow the pain-relieving effects of ibuprofen to last longer, they report in Molecular Pharmaceutics. And the approach could also be used to deliver other drugs orally that currently can only be taken intravenously.
Metal-organic frameworks are compounds made of metal ions linked to organic ligands, for drug delivery. Active ingredients can be packed inside the metal organic frameworks. They are porous, and some dissolve in water so are good candidates for drug couriers.
The researchers loaded ibuprofen into metal organic frameworks. The compounds were found to reach the bloodstream (of mice) quickly and lasted for twice as long as ibuprofen salts, which are the active ingredient in liquid gel formulations.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.
Biosimilars for people with rheumatoid arthritis and ankylosing spondylitis work as well and are as safe as the original biologic, says review
Biosimilars of anti-TNF-α agents have comparable efficacy and safety profile for use in people with rheumatoid arthritis and ankylosing spondylitis as their original biologic, a team outlines in the Journal of Autoimmunity.
Continue reading